Regular use of low-dose aspirin linked to a 20% higher risk of anemia in older adults

Researchers from Monash University, Melbourne conducted a post-hoc analysis of the ASPREE randomized controlled trial. The trial included 19,114 persons aged 70 years or older who were randomly assigned to take 100 mg of aspirin daily or placebo. Hemoglobin was measured annually, and ferritin was measured at baseline and 3 years after randomization. The data showed that the risk for developing anemia was 23.5 percent among those assigned to receive low-dose aspirin.

These results were accompanied by a small but greater decrease in mean hemoglobin and a greater decline in ferritin concentrations among those receiving aspirin. Differences in clinically significant bleeding events did not account for the overall difference in incident anemia or the decline in ferritin observed in ASPREE but was most likely due to occult blood loss given the observed steeper decline in ferritin in participants allocated to aspirin.

Reference: Effect of Low Dose Aspirin versus Placebo on Incidence of Anemia in the Elderly, Annals of Internal Medicine, DOI 10.7326/M23-0675